Neha Korde MD

PubMed

• Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.
  Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, Aaron Mitchell, Ross S Firestone
  JCO Oncology Practice. 2025-09-16
• Temporal genomic dynamics shape clinical trajectory in multiple myeloma.
  Francesco Maura, Marcella Kaddoura, Alexandra M Poos, Linda B Baughn, Bachisio Ziccheddu
  Nature Genetics. 2025-09-01
• Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance.
  Ross S Firestone, Anish K Simhal, Devin McAvoy, Eric M Jurgens, Juan-Jose Garcés
  Clinical Cancer Research. 2025-08-25

Abstracts/Posters

• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree
  Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018